Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, UK; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, UK.
Atherosclerosis. 2018 Dec;279:100-106. doi: 10.1016/j.atherosclerosis.2018.08.033. Epub 2018 Sep 6.
BACKGROUND & AIMS: A recently-validated, highly-sensitive T2 mapping magnetic resonance (MRI) technique accurately quantifies carotid plaque lipid. The aims of this study were to determine: (i) the extent of carotid plaque lipid in patients with acute coronary syndromes (ACS); (ii) the effects of initiation of high-intensity statin on plaque lipid content and (iii) whether plaque lipid content is related to standard or 'functional' blood lipid measurements.
Statin naïve subjects presenting with ACS underwent carotid artery MRI at 3 T scanner to quantify plaque lipid. Patients were subsequently commenced on high dose statin as part of clinical care and underwent a second MRI after three months. Plaque composition was measured using objective semi-automated techniques.
23 out of 24 patients had measurable lipid. Three months after statin initiation there was a significant reduction in carotid lipid percentage [from 10.3% (7.2-14.2) to 7.4% (5.4-10.0), p = 0.002] and a significant increase in fibrous percentage [from 83.3% ± 6.6-85.5% ± 4.8, p = 0.039]. None of the studied functional blood biomarkers were related to either baseline carotid plaque lipid content or its propensity to change with statin treatment.
T2-mapping demonstrated depleted carotid plaque lipid following the initiation of high-intensity statin treatment. Standard or 'functional' blood biomarkers were dissociated from plaque lipid content or changes with treatment. These findings further reinforce the importance of disease characterisation over risk factor assessment. Subject to clinical trial findings, quantification of plaque lipid may provide the basis for an approach to identify patients suitable for intensive lipid reduction regimes.
一种最近验证的、高度敏感的 T2 映射磁共振(MRI)技术可以准确量化颈动脉斑块脂质。本研究旨在确定:(i)急性冠状动脉综合征(ACS)患者颈动脉斑块脂质的程度;(ii)开始高强度他汀类药物治疗对斑块脂质含量的影响;(iii)斑块脂质含量是否与标准或“功能性”血脂测量有关。
在 3T 扫描仪上对他汀类药物初治的 ACS 患者进行颈动脉 MRI 以量化斑块脂质。随后,根据临床护理为患者开处方大剂量他汀类药物,并在三个月后进行第二次 MRI。使用客观的半自动技术测量斑块成分。
24 例患者中有 23 例可测量脂质。他汀类药物起始后三个月,颈动脉脂质百分比显著降低[从 10.3%(7.2-14.2)降至 7.4%(5.4-10.0),p=0.002],纤维百分比显著增加[从 83.3%±6.6%升至 85.5%±4.8%,p=0.039]。研究中的功能性血液生物标志物均与基线颈动脉斑块脂质含量或其随他汀类药物治疗变化的倾向无关。
T2 映射显示高强度他汀类药物治疗后颈动脉斑块脂质减少。标准或“功能性”血液生物标志物与斑块脂质含量或治疗变化无关。这些发现进一步强调了通过疾病特征描述来替代风险因素评估的重要性。基于临床试验结果,斑块脂质的定量可能为确定适合强化降脂治疗的患者提供依据。